Data from the Prostate Cancer Registry presented by Dr Simon Chowdhury (Guy's Hospital, London, UK) at ASCO 2016 indicate that, for men with mCRPC, whether or not the cancer is metastatic at initial diagnosis may be a critical indicator of future treatment and prognosis in mCRPC. Men with mCRPC who were M1 at primary diagnosis had higher PSA levels, increased incidence of bone lesions, and were more likely to have a reduced level of functioning, in terms of their ability to care for themselves, daily activity, and physical ability (measured by ECOG performance status scale) when compared with those who were M0 at diagnosis. These data can help to better inform the way we treat future mCRPC patients
Click here to see the poster.
Two sites in Luxembourg recruited a total of 15 registry participants.
.jpg)
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
